Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression

DAGMAR: Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression

The aim is to investigate if soy isoflavones and lignans affect markers of disease progression and gene expression among breast cancer patients receiving neo-adjuvant treatment in a three arm, double-blinded, randomized placebo-controlled trial (RCT) comparing: soy isoflavone supplementation, lignan supplementation, and placebo.

Inclusion Criteria:

• Diagnosed with breast cancer at "Brystkirurgisk Afdeling" at Rigshospitalet and Herlev Hospitals (within the last 30 days).
• Advised (and accepted) to receive neo-adjuvant treatment
• Primary unilateral breast cancer
• Treatment is expected to be curative
• Is expected to be able to attend surgery

Exclusion Criteria:

• Allergic to soy
• Celiac disease
• Inflammatory bowel disease
• Not understanding Danish (patient material and questionnaires are in Danish)
• Prior diagnosis of breast cancer
• Use of dietary supplements containing lignans or isoflavones three months prior to diagnosis